Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial
| dc.contributor.author | Dörner, Thomas | |
| dc.contributor.author | Kaul, Martin | |
| dc.contributor.author | Szántó, Antónia | |
| dc.contributor.author | Tseng, Jui-Cheng | |
| dc.contributor.author | Papas, Athena S. | |
| dc.contributor.author | Pylvaenaeinen, Ilona | |
| dc.contributor.author | Hanser, Malika | |
| dc.contributor.author | Abdallah, Nasri | |
| dc.contributor.author | Grioni, Andrea | |
| dc.contributor.author | Santos Da Costa, Aida | |
| dc.contributor.author | Ferrero, Enrico | |
| dc.contributor.author | Gergely, Péter | |
| dc.contributor.author | Hillenbrand, Rainer | |
| dc.contributor.author | Avrameas, Alexandre | |
| dc.contributor.author | Cenni, Bruno | |
| dc.contributor.author | Siegel, Richard M. | |
| dc.date.accessioned | 2023-12-20T07:33:11Z | |
| dc.date.available | 2023-12-20T07:33:11Z | |
| dc.date.issued | 2023 | |
| dc.date.oa | 2024-02-05 | |
| dc.date.pasync | 2024-01-27T00:07:07Z | |
| dc.date.updated | 2023-12-20T07:33:10Z | |
| dc.description.corrector | kzs | |
| dc.identifier.citation | Annals Of The Rheumatic Diseases. -[Epub ahead of print] (2023). -Ann. Rheum. Dis. - 0003-4967 | |
| dc.identifier.doi | http://dx.doi.org/10.1136/ard-2023-224691 | |
| dc.identifier.issn | 0003-4967 | |
| dc.identifier.opac | https://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM117457 | |
| dc.identifier.scopus | 85179435080 | |
| dc.identifier.uri | https://hdl.handle.net/2437/364092 | |
| dc.identifier.url | https://ard.bmj.com/lookup/doi/10.1136/ard-2023-224691 | |
| dc.identifier.wos | 001102556900001 | |
| dc.language | eng | |
| dc.rights.access | open access article | |
| dc.rights.owner | szerző | |
| dc.subject.mab | Orvostudományok | |
| dc.subject.mab | Klinikai orvostudományok | |
| dc.title | Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial | |
| dc.type | folyóiratcikk | |
| dc.type | idegen nyelvű folyóiratközlemény külföldi lapban |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 1 (Összesen 1)
Nincs kép
- Név:
- FILE_UP_0_ard-2023-224691.full.pdf
- Méret:
- 5.9 MB
- Formátum:
- Adobe Portable Document Format
- Leírás:
- kiadói változat